Engrail Therapeutics™ (Engrail) today announced that it has acquired NeuroCycle Therapeutics, a company focused on sub-type selective GABA-A modulation. The acquisition strengthens Engrail’s presence in the GABA-A space and provides a strong platform for initiation of clinical trials with multiple assets in 2021. “Our flexible transaction model and science-first approach allows us to acquire high-quality assets with a lower-risk path to market where significant patient need still exists,” said Vikram Sudarsan, Ph.D., CEO and president, Engrail Therapeutics.
Read the full article: Engrail Therapeutics Acquires NeuroCycle Therapeutics //
Source: https://www.businesswire.com/news/home/20210202005294/en/Engrail-Therapeutics-Acquires-NeuroCycle-Therapeutics